Wednesday, July 23, 2014

Amgen 1Q profit rises 21 percent on drug sales

April 23. 2013 4:41PM
Associated Press

Story Tools
PrintPrint | E-MailEMail | SaveSave | Hear Generate QR Code QR
Send to Kindle

(AP) Biotech giant Amgen Inc. says its first-quarter profit rose 21 percent on higher sales of drugs to treat arthritis and osteoporosis.

The company on Tuesday reported net income of $1.43 billion, or $1.88 per share, from $1.18 billion, or $1.48 per share, in the prior-year period. Adjusted earnings were $1.96 per share.

Revenue rose 5 percent, to $4.24 billion.

Analysts polled by FactSet expect earnings per share of $1.84 on sales of $4.37 billion.

Sales of the Thousand Oaks, Calif., company's biotech drugs were driven by growth of Enbrel for psoriasis and rheumatoid arthritis and Prolia for osteoporosis.

Sales of anemia drugs Aranesp and Epogen continued their long slide due to limits on dosing and reimbursement because of safety concerns.

Shares are off 4.7 percent to $107.42 in after-hours trading.

Associated Press

comments powered by Disqus Commenting Guidelines
Mortgage Minute

Search for New & Used Cars

Used New All

Search Times Leader Classifieds to find just the home you want!

Search Times Leader Classifieds to find just what you need!

Search Pet Classifieds
Dogs Cats Other Animals

Social Media/RSS
Times Leader on Twitter
Times Leader on Youtube
Times Leader on Google+
The Times Leader on Tumblr
The Times Leader on Pinterest
Times Leader RSS Feeds